Skip to content

Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia

Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01151267
Enrollment
44
Registered
2010-06-28
Start date
2009-07-31
Completion date
2012-10-31
Last updated
2013-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Surgery

Keywords

Isocapnic hyperpnoea (IH), Anesthesia, Accelerate elimination of inhalation agents, Recovery from anesthesia

Brief summary

The rate of elimination of inhalation agent is directly proportional to the degree of alveolar ventilation. Using Isocapnic Hyperpnoea (IH) device, it is possible to maintain constant end-tidal CO2 with increased minute ventilation. This is achieved by passively adding a flow of CO2 to the inspirate in proportion to increases in ventilation above the baseline. In animal and human studies IH shortens the time of awakening from isoflurane and sevoflurane anesthesia when manual positive pressure ventilation is applied. IH device could be used for spontaneous hyperpnoea as well. The investigators want to compare recovery times from sevoflurane anesthesia in patients with application of hypercapnic spontaneous hyperpnoea (HSH) versus the standard anesthesia protocol (controls). 44 patients ill be randomized to either HSH facilitated recovery, or conventional recovery (controls).The time intervals from the end of anesthesia (turning off the vaporizer) until recovery milestones will be recorded.

Interventions

OTHERStandard Anesthesia management for post surgical patients

The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.

DEVICEHypercarbic Spontaneous Hyperpnoea

Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* elective gynecological surgery * age 18-80 * ASA I-III * informed consent

Exclusion criteria

* ASA IV-V, * contra-indications to sevoflurane anesthesia or other anesthetics included in the protocol * history of cardiac or respiratory disease * intracranial pathology * alcohol or drug abuse * psychiatric illness and/or medications

Design outcomes

Primary

MeasureTime frame
Time from the end of anesthesia to the readiness for post-anesthesia care unit (PACU) discharge.End of anesthesia (turning off the vaporizer) until readiness for PACU discharge, approximately 30 minutes to 2 hours

Secondary

MeasureTime frame
Comparison of pain and sedation scoresEnd of anesthesia (turning off the vaporizer) to PACU discharge, approximately 30 minutes to 2 hours

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026